Columbia University and Health Fidelity, Inc. announced today that they have entered into a license agreement for commercialization of Columbia's MedLEE Natural Language Processing technology. The license grants Health Fidelity exclusive rights to a portfolio of patents, software code, and trademarks for commercialization of MedLEE-related products and services dedicated to improving healthcare.
"We're delighted to be commercializing MedLEE, one of the most reliable and heavily used clinical natural language processing (NLP) engines," said Dan Riskin, CEO of Health Fidelity. "Through natural language processing technology, Health Fidelity enables medical practitioners and administrators to effectively make use of the wealth of information they collect so they can make better medical decisions, monitor and improve quality of care, and enable R&D that will bring us to the next frontier in healthcare. Our Fidelity Platform incorporates this technology and provides a robust, high quality, cloud-based clinical NLP platform that easily integrates with and improves the capabilities of our solution partners' applications."
Clinical NLP supports automated extraction of discrete medical information, critical to meeting goals in Meaningful Use, accountable care organizations (ACO), and ICD 10 conversion. Through two decades of development and improvement, MedLEE (Medical Language Extracting and Encoding) has the most associated peer reviewed publications of any clinical NLP engine and is associated with many of the earliest patents in the space.